Antiplatelet therapy around CABG: the latest evidence.

ABSTRACT:

Purpose of review

The optimal antiplatelet strategy in patients after coronary artery bypass graft (CABG) surgery is unclear. We review the evidence on the efficacy and safety of DAPT after CABG and discuss potential novel antiplatelet strategies that reduce the risk of bleeding without loss of efficacy.

Recent findings

Adding the potent P2Y12 inhibitor ticagrelor to aspirin for 1 year after CABG is associated with a reduction in the risk of vein graft failure, at the expense of an increased risk of clinically important bleeding. Ticagrelor monotherapy is not associated with better efficacy than aspirin alone, but is not associated with increased bleeding risk.

Summary

Dual antiplatelet therapy (DAPT) is recommended after acute coronary syndrome events, but aspirin as

SUBMITTER: Sandner S 

PROVIDER: S-EPMC10552805 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature